(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 April 2009 (23.04.2009)

PCT

(10) International Publication Number
WO 2009/049841 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2008/008635

(22) International Filing Date: 13 October 2008 (13.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07020120.7 15 October 2007 (15.10.2007) EP

(71) Applicants *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **GLYCART BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 18, CH-8952 Schlieren-Zuerich (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FRIESS, Thomas** [DE/DE]; St. Martin-Strasse 8a, 86911 Diessen-Dettenhofen (DE). **KLEIN, Christian** [DE/DE]; Moraenenweg 5, 82393 Iffeldorf (DE). **STREIN, Pamela** [DE/DE]; Panamastrasse 14, 69469 Weinheim (DE). **UMANA, Pablo** [CH/CH]; Milchbuckstrasse 3, CH-8057 Zuerich (CH).

(74) Agent: **BURGER, Alexander**; Roche Diagnostics GmbH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) Title: COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT

Fig. 1



(57) Abstract: The present invention is directed to the use of a type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with an anti-Bcl-2 active agent.

WO 2009/049841 A1

Published:

— *with international search report*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*